PACIRA BIOSCIENCES INC (PCRX) Stock News
NASDAQ:PCRX - Nasdaq - US6951271005 - Common Stock
PCRX Latest News and Analysis
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX)....
Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments
Pacira BioSciences, Inc. Class Action: Levi & Korsinsky Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities...
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of...
Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - PCRX
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of...
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities...
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit...
Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRX
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of...
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pacira BioSciences, Inc. ("Pacira" or...
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of...
Stockholder Notice: Robbins LLP Informs Stockholders of the Pacira BioSciences, Inc. Class Action Lawsuit
/PRNewswire/ -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira...
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
Rosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock with good fundamentals.
PCRX Makes Bullish Cross Above Critical Moving Average
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
Company also reports preliminary unaudited 2024 revenue of $701.0 million
Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 43rd Annual J.P....
DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.
/PRNewswire/ -- DOMA Perpetual Capital Management LLC (together with its affiliates, "DOMA"), which beneficially owns approximately 4.14% of the outstanding...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative,...
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
-- First in new family of EXPAREL patents -- -- Expands EXPAREL intellectual property and provides protection into 2044 -- PARSIPPANY, N.J., Dec. 03,...
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting --
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting --...